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BACKGROUND: Antimicrobial resistance (AMR) is one of the most significant health threats to society. A growing body of research demonstrates
selection for AMR likely occurs at environmental concentrations of antibiotics. However, no standardized experimental approaches for determining
selective concentrations of antimicrobials currently exist, preventing appropriate environmental and human health risk assessment of AMR.
OBJECTIVES:We aimed to design a rapid, simple, and cost-effective novel experimental assay to determine selective effect concentrations of antibiot-
ics and to generate the largest experimental data set of selective effect concentrations of antibiotics to date.
METHODS: Previously published methods and data were used to validate the assay, which determines the effect concentration based on reduction of
bacterial community (wastewater) growth. Risk quotients for test antibiotics were generated to quantify risk.
RESULTS: The assay (SELection End points in Communities of bacTeria, or the SELECT method) was used to rapidly determine selective effect con-
centrations of antibiotics. These were in good agreement with quantitative polymerase chain reaction effect concentrations determined within the
same experimental system. The SELECT method predicted no effect concentrations were minimally affected by changes in the assay temperature,
growth media, or microbial community used as the inoculum. The predicted no effect concentrations for antibiotics tested ranged from 0:05 lg=L for
ciprofloxacin to 1,250 lg=L for erythromycin.
DISCUSSION: The lack of evidence demonstrating environmental selection for AMR, and of associated human health risks, is a primary reason for the
lack of action in the mitigation of release of antibiotics into the aquatic environment. We present a novel method that can reliably and rapidly fill this
data gap to enable regulation and subsequent mitigation (where required) to lower the risk of selection for, and human exposure to, AMR in aquatic
environments. In particular, ciprofloxacin and, to a lesser extent, azithromycin, cefotaxime, and trimethoprim all pose a significant risk for selection
of AMR in the environment. https://doi.org/10.1289/EHP6635
Introduction
By 2050, it is estimated that one person will die from an
antimicrobial-resistant (AMR) infection every 3 s (O’Neill
2016). The environment is a recognized reservoir of AMR bac-
teria and genes. However, antimicrobial compounds are also
discharged into the environment from a range of sources,
including (but not limited to) industrial, hospital, and domestic
wastewater, as well as runoff from agricultural land (Kümmerer
2004).
The U.S. Environmental Protection Agency (U.S. EPA 2017)
and the European Chemicals Agency (ECHA 2013) have out-
lined the stages required for human health risk assessment. The
intended outcome is complete risk characterization, which is
informed by exposure assessment, hazard identification, and haz-
ard characterization (ECHA 2013; U.S. EPA 2017). In terms of
human health risk assessment of AMR, there are significant
knowledge gaps within this framework preventing complete risk
characterization, particularly in terms of hazard identification and
characterization.
For example, in terms of hazard characterization of AMR,
dose–response relationships between exposure to AMR bacteria
or genes and adverse health outcomes have not yet been clearly
defined. However, recent research has found high exposure to
coastal waters to be associated with higher human gut carriage of
clinically important, AMR Escherichia coli (E. coli) responsible
for serious, extra-intestinal infections (Leonard et al. 2018).
Identified hazards to human health relevant for risk assessment of
AMR are the presence of AMR bacteria and genes or the pres-
ence of antimicrobial agents and other selective compounds
(which directly influence the prevalence of AMR genes and
AMR bacteria). The number of studies that focus on the preva-
lence of AMR genes in bacteria in environmental compartments
has increased rapidly in recent years (Ashbolt et al. 2013), but
there are still very few experimental data on selective concentra-
tions of antibiotics that can cause an increase in numbers of
AMR bacteria or AMR genes.
The first experimental study to show selection for AMR at
environmentally relevant antibiotic concentrations used isogenic-
resistant and susceptible E. coli in competition assays to deter-
mine the minimal selective concentration of a test antibiotic
(Gullberg et al. 2011). Since then, several studies have investi-
gated the selection for AMR in complex bacterial communities to
take into account competition within and between different bacte-
rial taxa that may occur in the natural environment and poten-
tially alter such effect concentrations (Klümper et al. 2019;
Kraupner et al. 2018; Lundström et al. 2016; Murray et al. 2018;
Stanton et al. 2020). However, all of these approaches require
specialist equipment and personnel and are prohibitively expen-
sive to be conducted routinely.
Currently, an environmental risk assessment of antibiotics is
required when the predicted environmental concentration exceeds
10 ng=L in Europe (EMA 2006) or 100 ng=L in the United States
(FDA 1998). The standard approach is to calculate a risk quotient
(RQ) by dividing a predicted environmental concentration or
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measured environmental concentration (MEC) by a predicted no
effect concentration (PNEC). PNECs are derived by applying an
assessment factor to a no observed effect concentration (NOEC),
which is determined through standardized ecotoxicological tests
(EMA 2006) and represents the test concentration directly below
the lowest observed effect concentration (LOEC). NOECs for anti-
biotics are currently determined using several different ecotoxico-
logical tests, including the activated sludge respiration inhibition
test (ASRIT) and toxicity tests on species such asDaphnia magna,
fish, cyanobacteria, or green algae (Le Page et al. 2017). None of
these experimental methods directly consider the selective poten-
tial of an antibiotic, and most do not focus on the target organism
(bacteria). As a result, the risk of selection for AMR occurring in
aquatic environments is neither understood nor addressed within
current environmental risk assessments. A standardized experi-
mental approach is therefore required to inform safe release limits
of antibiotics to prevent environmental selection for AMR.
Such an experimental method would be invaluable for human
health risk assessment hazard identification by characterizing the
hazard posed by a specific concentration of an antibiotic or other
selective agent in terms of selecting for AMR. For example, it
could identify hotspots in the environment that contain levels of
antibiotics likely to select for antibiotic-resistant bacteria or anti-
biotic resistance genes to which humans may be exposed
(Ashbolt et al. 2013). Together these data could be used to lower
the likelihood of environmental transmission of resistant bacteria
or resistance genes to humans and animal-associated bacteria,
thereby protecting the efficacy of novel antibiotics and promoting
appropriate stewardship of antibiotics currently in use. Currently,
no such standardized experimental method has been designed or
validated that can quantify the risk that antibiotics in the environ-
ment pose in terms of selecting for AMR in environmental and
human health risk assessments. Development of such a method
was the aim of the present study.
The minimal selective concentration is defined as the lowest
antibiotic concentration at which the growth rate of resistant and
susceptible bacteria are equal (Gullberg et al. 2011). Therefore,
when a reduction in bacterial growth is observed over time as a
result of antibiotic exposure, this may indicate selection is occur-
ring. Furthermore, a mathematical model was recently described
that estimated the minimal selective concentration and which
took into account the growth rates of resistant and susceptible
bacterial strains under different antibiotic pressures (Greenfield
et al. 2018). A loss in net growth, particularly of the susceptible
strain, was shown to be the most sensitive parameter for minimal
selective concentration prediction (Greenfield et al. 2018).
Therefore, we hypothesized any significant reduction in growth
of a complex bacterial community over time under a given antibi-
otic exposure concentration could be used as an end point to pre-
dict selection for AMR.
In the present study, we present the largest data set of experi-
mentally derived selective effect concentrations of antibiotics
currently available, using a novel growth-based approach. This
SELection End points in Communities of bacTeria (or SELECT
method) determines the LOECs of antibiotics as the concentra-
tion during the exponential growth phase where the net growth of
the bacterial community is significantly reduced. PNECs for re-
sistance [PNECRs (Bengtsson-Palme and Larsson 2016)] and
RQs for all test antibiotics were determined, demonstrating this
new approach can be used to rapidly fill crucial data gaps, ena-
bling appropriate environmental and human health risk assess-
ment of antibiotics in terms of their potential to select for AMR.
The SELECT method was validated by comparing SELECT
PNECRs to genotypic PNECRs that were derived using a previ-
ously published method (Murray et al. 2018).
Methods
Test Antibiotics
Antibiotics used in the present study were cefotaxime (Acros
Organics; 454950010), ciprofloxacin (Sigma-Aldrich; 17850), tri-
methoprim (Sigma-Aldrich; T7883-5G), azithromycin (Sigma-
Aldrich; PHR1088), clarithromycin (Molekula; 37077446), eryth-
romycin (Acros Organics; AC227330050), gentamicin (Acros
Organics; 455310010), and chloramphenicol (Acros Organics;
227920250). Solvents were sterile water, dilute hydrochloric acid
(0:1 M; Fisher Chemical; 10080210), dimethyl sulfoxide (100%;
Sigma-Aldrich; D8418-50ML), ethanol (100%; Fisher Bioreagents;
BP2818-4), acetone (100%; Acros Organics; 444150050), ethanol
(100%), sterile water, and sterile water, respectively. All antibiotics
were stored in single-use aliquots at−20C until use.
Sewage Samples
Influent and effluent samples were collected from wastewater
treatment plant (WWTP) A (serving a population of approxi-
mately 43,000) in October 2016 and February 2018. Influent
samples were collected from WWTP B (serving a population of
approximately 77,000) in February 2018. Samples were trans-
ported in cool boxes, then mixed 1:1 with 40% glycerol (Fisher;
G/0600/17) and stored at −80C until use.
Experimental and Statistical Approach for Determination of
Genotypic NOECs
Thawed sewage samples were spun down at 3,000× g for 10 min
and resuspended in 0.85% sterile sodium chloride (NaCl; Fisher
Chemical; S/3,160/60) twice to remove chemical and nutrient car-
ryover. The resuspended pellet was used to inoculate at 10% (vol/
vol) in Iso-Sensitest™ broth (Oxoid; CM0473). Microcosms
spiked with antibiotic were shaken at 180 rpm for 24 h at 37°C.
Each day, 50 lL of overnight culture was transferred into 5 mL
fresh medium and fresh antibiotic, for a total of 7 d. Two 1-mL ali-
quots of each culture were spun down at 21,000× g for 2 min,
resuspended in 20% glycerol (Fisher; G/0600/17), and frozen at
−80C until DNA extraction at the beginning (Day 0) and at the
end of the experiment (Day 7). The following antibiotic concentra-
tions were used, each with five biological replicates: 4,000 lg=L
and 2-fold dilutions down to 15:63 lg=L for trimethoprim,
4,000 lg=L and 2-fold dilutions down to 62:5 lg=L for gentami-
cin, and 8,000 lg=L and 2-fold dilutions down to 62:5 lg=L for
chloramphenicol.
Effect concentrations were determined using the intI1 gene tar-
get given that the genes conferring resistance (i.e., dfr or aac genes)
to these compounds are commonly associated with class 1 inte-
grons, which are genetic platforms that can readily integrate a
diverse range of mobile AMR genes (Partridge et al. 2009). The
LOEC was determined as the test concentration at which the intI1
prevalence was significantly higher than the no-antibiotic control.
The cefotaxime (Murray et al. 2018), ciprofloxacin (Stanton
et al. 2020), and macrolide (azithromycin, clarithromycin, and
erythromycin) (Stanton et al. 2020) week-long experiments were
conducted as part of previously published studies. The concentra-
tion range in the previous study for cefotaxime was 2,000 lg=L,
with 2-fold dilutions down to 15:625 lg=L (Murray et al. 2018).
For cefotaxime, the compound-specific gene end point (blaCTX-M)
LOEC was taken directly from the previous study by Murray et al.
(2018). The present study also reanalyzed the cefotaxime data
from Murray et al. (2018) with additional quantitative polymer-
ase chain reaction (qPCR) to determine the LOEC of cefotaxime
using the intI1 gene target. The concentrations used in the mac-
rolide experiments conducted previously were 100,000 lg=L,
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10,000 lg=L, 1,000 lg=L, 750 lg=L, 500 lg=L, 250 lg=L, and
100 lg=L (Stanton et al. 2020). The concentration range for the
ciprofloxacin experiment conducted previously was 1,000 lg=L,
with 2-fold dilutions down to 0:98 lg=L (Stanton et al. 2020). The
LOEC data for the macrolides (determined using both the intI1 gene
target and the compound-specific gene target, ermF) and the LOEC
data for ciprofloxacin (intI1 gene target) were taken directly from
the previously published study by Stanton et al. (2020).
DNA extraction was performed using the DNeasy Ultra-Clean
Microbial kit (Qiagen; 12,224-250, previously sold byMBio as the
Ultra-Clean kit) according to the manufacturer’s instructions.
DNA was diluted 5-fold (Day-0 samples) to 20-fold (Day-7 sam-
ples) to dilute out qPCR inhibitors. DNA quantification was not
performed because standard curves were used for absolute quanti-
fication. Standard curves were generated with custom synthetic
gBlocks™ (Table S1) provided by IDTDNA, prepared according
to the manufacturer’s instructions and stored in single-use aliquots
at −20C. qPCR was performed using the PrimerDesign Precision
Plus SYBR™ Green Master Mix (PPLUS-machine type-10ML),
on the Applied Biosystems StepOne™ machine (catalog number
4,376,357, serial number 272,007,340). Reactions comprised
10 lL Master Mix, 5 lL template, 2 lL primer (1 lL each of for-
ward and reverse primers, all 10 lL except 16S rRNA, which was
9 lL), 0:2 lL bovine serum albumin (20 mg=mL, Sigma-Aldrich;
A2153-10G), and water up to a final volume of 20 lL. Cycling pa-
rameters used were a 2-min initial Hot Start activation at 95°C, fol-
lowed by 40 cycles of data collection with 10 s at 95°C and 60 s at
60°C. All the primers used in the present study, as well as the pri-
mers used to generate the (blaCTX-M) prevalence data in the previ-
ous study on cefotaxime (Murray et al. 2018) and the primers used
to generate all reported (ermF and intI1) prevalence data for cipro-
floxacin and the macrolides (Stanton et al. 2020) are listed in Table
S1 andwere provided by IDTDNA.
Kruskal-Wallis tests were used to check that there were no sig-
nificant differences between treatments at Day 0. LOECs were
determined as the lowest antibiotic concentration where the preva-
lence at Day 7was significantly higher than theDay-7 no-antibiotic
control, according to Dunn’s test or generalized linear models
(GLMs; whichever was the most protective, i.e., yielded the
LOEC). GLMs were used to calculate qPCR LOECs for ciproflox-
acin (Gamma; identity link), trimethoprim, chloramphenicol, and
gentamicin (Gamma; log link for all three); all other data were ana-
lyzed using Dunn’s test. If the prevalence at Day 7 was greater than
the prevalence at Day 0, then positive selection was considered to
have occurred; if less, then significant persistence was considered
to have occurred (Murray et al. 2018; Stanton et al. 2020). NOECs
were assigned as the test concentration directly below the LOECs,
at which no significant differences in resistance were observed
according to either Dunn’s Tests or GLMs.
Experimental and Statistical Approach for Determination of
SELECT NOECs
SELECT method tests were conducted in 96-well plates with
washed sewage as described above and inoculated into Iso-
Sensitest™ broth (Oxoid; CM0473) at 10% (vol/vol). There were
six replicates per antibiotic or control treatment. There were no
significant differences between the solvent controls and the no-
antibiotic controls (all p>0:05; Excel Table S1). All raw data for
the solvents and the corresponding no-solvent controls, means,
standard deviations, and standard errors of the mean are listed in
Excel Table S2. Therefore, the experimental runs contained only
a no-antibiotic control and a sterile-broth control.
The rationale behind the concentration ranges was as follows.
For cefotaxime, ciprofloxacin, trimethoprim, gentamicin, and
chloramphenicol, the highest concentration used was the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
clinical break point concentration for Enterobacteriaceae
(EUCAST 2019). These were 2,000 (cefotaxime), 1,000 lg=L
(ciprofloxacin), 4,000 lg=L (trimethoprim), 4,000 lg=L (genta-
micin), and 8,000 lg=L (chloramphenicol), followed by 2-fold
dilutions down to the low micrograms-per-liter range and until a
NOEC could be determined. For the macrolides (azithromycin,
clarithromycin, and erythromycin), EUCAST clinical break point
concentrations for Enterobacteriaceae were not available
(EUCAST 2019). For azithromycin, the EUCAST clinical break
point concentration for Salmonella was used (16,000 lg=L)
(EUCAST 2019), followed by 2-fold dilutions down to the low
micrograms-per-liter range and until a NOEC could be determined.
Nominal starting concentrations for clarithromycin and erythro-
mycin were selected as 10,000 and 100,000 lg=L, respectively,
followed by 2-fold dilutions down to the low micrograms-per-liter
range and until a NOEC could be determined. The higher starting
concentration for erythromycin was based on previous research
that indicated erythromycin is less potent than azithromycin (Jelić
andAntolović 2016).
Concentrations used were the same as in the week-long geno-
typic experiments but with extra 2-fold dilutions to lower concen-
trations where necessary to determine a LOEC. Where a lowest
effect concentration could not be observed in a single run (i.e., test-
ing 14 different concentrations), a second plate was run. These
additional plates started at the lowest one or two test concentrations
from the previous plate and down until a LOEC could be observed.
Plates were incubated at 37°C in a Varisokan Flash (catalog
number N06354, serial number 3001–1778) or BioTek Synergy
(serial number 254,462) plate reader at medium shaking or
120 rpm, respectively. Optical density (OD) at 600 nm readings
were performed every hour for 12 h up to 60 h (depending on cul-
turing conditions) to allow the bacterial community to reach the
stationary growth phase.
Variations of the SELECT assay were performed—using
WWTP A (2016), WWTP A (2018), and WWTP B (2018) influ-
ent, as well as WWTP A (2018) effluent as the inoculum. For
these inoculum variations, experiments were conducted as
described above for azithromycin, cefotaxime, ciprofloxacin, and
trimethoprim. To determine the potential effects culture condi-
tions had on effect concentration, the medium was replaced with
artificial sewage and experiments were run at room temperature
(21C±2C), as per the ASRIT (OECD 2009), for the four anti-
biotics azithromycin, cefotaxime, ciprofloxacin, and trimetho-
prim using the WWTP A 2018 inoculum. The artificial sewage
recipe is described in the ASRIT (OECD 2009) and was prepared
by mixing 16 g peptone (Oxoid; LP0085), 11 g meat extract
(Fluka Analytical; 70164-500G), 3 g urea (Fisher; U/0500/53),
0:7 g NaCl (Fisher; S/3,120/60), 0:4 g calcium choride dihydrate
(Sigma; C7902-500g), 0:2 g magnesium sulfate heptahydrate
(Sigma-Aldrich; 230391-500g), and 2:8 g dipotassium phosphate
(Acros Organics; 205925000) in 1 L deionized water. This artifi-
cial sewage concentrate was autoclaved and stored in the dark at
4°C. Hundredfold dilutions were prepared from the stock concen-
trate by mixing 1 mL concentrate with 100 mL autoclaved water.
Cefotaxime, ciprofloxacin, and trimethoprim were chosen for
these additional tests because they resulted in the lowest PNECRs
determined using the SELECT method standard culturing condi-
tions (see the “Results” section). Azithromycin was also included
as the macrolide with the lowest SELECT PNECR (see the
“Results” section) of the macrolides currently on the Water
Framework Directive (WFD) Watch List.
To determine the LOEC, first, the time point that exhibited the
strongest dose–response relationship between overall community
growth (OD600) and antibiotic concentration was determined using
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Pearson’s correlation or Spearman’s rank correlation (depending
onwhether the datawere distributed normally or not, respectively).
All LOECswere determined using Spearman’s rank, except for tri-
methoprim using WWTP B influent. Dunn’s test was then per-
formed on data at this time point to identify the concentration of
antibiotic that significantly reduced the growth of the community
comparedwith the no-antibiotic control (p<0:05).
Statistical Comparison of the Two Experimental Approaches
The Bland-Altman analysis is a method commonly used in clini-
cal studies to assess the level of agreement between measure-
ments generated through two different methods (Bland and
Altman 1986). This is a preferred analysis method to correlation,
which considers only positive or negative relationships between
data measurements (Giavarina 2015). To account for the large
range in NOECs (i.e., the large range in measurements included
in the analysis), the Bland-Altman analysis was performed using
logged PNECRs as previously recommended (Giavarina 2015).
Significant agreement between the two experimental approaches
is indicated by all differences lying within the upper and lower
limits of agreement (i.e., within 95% confidence intervals around
the mean for all measurements).
Calculation of PNECRs and RQs
For both SELECT and qPCR methods, PNECRs were determined
by applying an assessment factor of 10 to the NOEC (EMA
2006). Median MEC (MECmed) and maximum MEC (MECmax)
values for all antibiotics included in the present study (except
gentamicin) were extracted from the Umweltbundesamt (UBA)
database (UmweltBundesamt 2019). MECmeds that excluded non-
detects are presented in the main text; MECmeds that included the
nondetects are presented in Figure S1. Nondetect MECs were
included in the median calculation as 0 lg=L from studies where
quantification was attempted but could not be performed due to
concentrations being below the limit of detection or quantifica-
tion. MECs included all human sewage and WWTP types of sam-
ple (i.e., livestock and industrial samples were excluded, as were
unknowns). Only MECs where the emission source was listed as
urban or hospital wastewater were included, as were MECs
where the original measurement unit was per liter (i.e., only
aquatic samples). All MECs were rounded to two decimal places
before RQ calculations. For erythromycin MECs, erythromycin,
erythromycin hydrate, and erthryomycin A dihydrate were
included. All MEC values are presented in Excel Table S3; maxi-
mum and median values are presented in Excel Table S4.
For gentamicin, MEC data from only a single study were
available, so predicted environmental concentration data were
used. European consumption data (retail, prescription, and hospi-
tal data, in kilograms) for 2015 were obtained from IMS Health
for gentamicin use in 22 European countries. Country-specific
total substance predicted environmental concentrations were esti-
mated assuming the following: even use across the whole popula-
tion for each country (calculated as mass per person per day),
100% patient use and no wastage, no patient metabolism or sew-
age treatment removal, and each person generating 200 L of
wastewater per day [as defined for a Phase-1 predicted environ-
mental concentration determination (EMA 2006), but without a
final dilution factor of 10 so as to represent effluent concentra-
tions as opposed to surface-water concentrations].
Median RQs (RQmed) and maximum RQs (RQmax) were
derived by dividing MECmed and MECmax values, respectively,
by the lowest SELECT PNECRs determined in the present study.
Risk of selection for AMR was classified as low, medium, or
high based on RQs of <0:1, 0:1 to<1 and >1, respectively.
Results
PNECRs Determined through qPCR in the Present Study
and Previously Published Studies
In the present study, qPCR data were generated to calculate cefo-
taxime intI1 prevalence, trimethoprim intI1 prevalence, gentami-
cin intI1 prevalence, and chloramphenicol intI1 prevalence
(Figure 1; raw data are presented in the Excel file alongside the
averages, standard deviations, and standard errors of the mean).
qPCR data for clarithromycin, azithromycin, and erythromycin
(to calculate prevalence of both ermf and intI1) were reported
previously (Stanton et al. 2020). qPCR data for cefotaxime [to
calculate (blaCTX-M) prevalence] were also reported previously
(Murray et al. 2018). A summary of all the qPCR effect concen-
trations determined in the present study and previous studies
(Murray et al. 2018; Stanton et al. 2020) using the genotypic
(qPCR) end points are presented in Table 1.
The LOEC for ciprofloxacin was determined as 15:63 lg=L by
Stanton et al. (2020) using the intI1 gene target. For all other antibi-
otics with two gene target effect concentrations (i.e., the macro-
lides), the compound-specific gene target data were determined as
the most protective by Stanton et al. (2020). The exception was
cefotaxime, where the (blaCTX-M) LOEC determined previously by
Murray et al. (2018) was identical to the intI1 LOEC generated in
the present study (Figure 1). PNECRs ranged from 0:78 lg=L
[ciprofloxacin for gene target intI1 (Stanton et al. 2020)] to
50 lg=L [azithromycin, clarithromycin, and erythromycin for
gene target ermF (Stanton et al. 2020)] (Table 1).
SELECT PNECRs and Comparison to qPCR PNECRs
A summary of all the SELECT data determined are shown in
Table 1. PNECRs ranged from 0:05 lg=L for ciprofloxacin to
1,250 lg=L for erythromycin. The most protective qPCR and
SELECT PNECRs determined to date are shown in Figure 2. The
error bars represent the span of the test concentrations above and
below theNOEC.Overall, therewas very good agreement between
the two methods, with the span for all PNECRs overlapping except
for two macrolides (erythromycin and clarithromycin) and cipro-
floxacin. For the macrolides, this was using the compound-specific
qPCR target (i.e., ermF) (Stanton et al. 2020). However, when
using the intI1 gene targets, the qPCR (Stanton et al. 2020) and
SELECTPNECRs for erythromycin and clarithromycin weremore
comparable (Figure S2). PNECRs derived using the SELECT
methodwere identical or more protective than the qPCRmethod in
all cases, except for erythromycin and clarithromycin, when using
the more protective compound-specific gene target ermF reported
previously (Stanton et al. 2020) (Figure 2).
Bland-Altman statistical analysis was also performed to deter-
mine the level of agreement between PNECRs derived using the
two experimental methods (Figure S3). All data points lay within
the upper and lower limits of agreement, with the exception of
erythromycin. However, the erythromycin PNECR was still
within the absolute limits of agreement, demonstrating that the
two methods provided statistically very similar measurements.
Spatiotemporal Effects on SELECT PNECRs
Several variations in bacterial community inoculum were tested
to determine whether this affected the PNECRs derived using the
SELECT method. These variations included comparing influent
samples from the same WWTP (i.e., A) at two times points (2016
and 2018), influent and effluent from the same WWTP (i.e., A),
and influent from two different WWTPs (A and B; the latter of
which served a larger population in a different part of the UK). In
many cases, SELECT PNECRs were the same (Figure S4). There
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were some differences in SELECT PNECRs, depending on sam-
pling year and sampling site, but all SELECT PNECRs werewithin
a factor of 2, with the exception of ciprofloxacin—where the
SELECT PNECR for the 2016WWTP A influent sample was one-
fourth that of the PNECR of the WWTP B influent 2018 sample—
and for trimethoprim—where the PNECR for the 2016 WWTP A
influent sample was one-fourth that of the PNECR of all other
SELECT PNECRswithWWTP variations for this antibiotic.
Assessing Effects of Culturing Conditions on SELECT
PNECRs
Low-temperature, artificial sewage SELECT PNECRs (Table 1;
Figure S5) were, in some cases, identical to the SELECT
PNECRs determined at a higher temperature and in Iso-
Sensitest™ broth. PNECRs were within a factor of two (with the
exception of trimethoprim, where the artificial sewage, 21°C
PNECR was one-fourth that of the Iso-Sensitest™ broth, 37°C
PNECR and ciprofloxacin, where all PNECRs were within the
same order of magnitude). No one condition was more protective
across all antibiotics; that is, for cefotaxime and ciprofloxacin,
the artificial sewage and 21°C condition was more protective, but
for azithromycin and trimethoprim, the Iso-Sensitest™ broth and
37°C condition was more protective.
The Risk of Selection for AMR Posed by Different
Antibiotics
For the present study, RQmed=max were determined by dividing
MECmed=max (medium/maximum predicted environmental con-
centration, see the “Methods” section; Figure 3, and Figure S1)
by the lowest SELECT PNECRs determined in the present study.
Overall, RQmed=max for most antibiotics were within the accepta-
ble range (i.e., RQ <1). However, several antibiotics posed unac-
ceptable risks. These were azithromycin (RQmax), cefotaxime
(RQmax), trimethoprim (RQmax), and ciprofloxacin (both RQmax
Figure 1. Average intI1 prevalence (intI1 copy number/16S rRNA copy number) at the beginning (Day 0, gray bar) and end (Day 7 or Day 8, black bar) of the evolu-
tion experiments for (A) cefotaxime, (B) chloramphenicol, (C) gentamicin, and (D) trimethoprim. n=5 for each antibiotic treatment for each day, except gentamicin
4,000 lg=L Day 7 (n=4) and trimethoprim 4,000 lg=L Day 7 (n=3). For cefotaxime (A): **, p<0:05 (significantly different) to Day 8 no-antibiotic control,
Dunn’s test—positive selection; X, p<0:1 (significantly different); XX, p<0:05 (significantly different) to Day 8 no-antibiotic control, Dunn’s test—significant
increased persistence. p-Values were 0.0888 (62:5 lg=L), 0.0050 (125 lg=L), 0.0003 (250 lg=L), 0.0070 (500 lg=L), 0.0033 (1,000 lg=L), and 0.0374
(2,000 lg=L). For chloramphenicol (B): **, p<0:05 (significantly different) to Day 7 no-antibiotic control, gamma general linearized model, log link—positive
selection. p-Values were 0.0012 (500 lg=L), 0.0021 (1,000 lg=L), 0.02,348 (2,000 lg=L), 0.0029 (4,000 lg=L), and 0.0004 (4,000 lg=L). For gentamicin (C): **,
p<0:05 (significantly different) to Day 7 no-antibiotic control, *, p<0:1 (significantly different), gamma general linearizedmodel with log link—positive selection.
p-Values were 0.0213 (250 lg=L), 0.0508 (500 lg=L), 0.0012 (2,000 lg=L), and 0.0266 (4,000 lg=L). For trimethoprim (D): **, p<0:05 (significantly different)
to Day 7 no-antibiotic control, gamma general linearized model, log link—positive selection. p-Values were 0.0002 (62:5 lg=L), 0.0002 (125 lg=L), 4:42× 10−7
(250 lg=L), 1:36× 10−7 (500 lg=L), 1:25× 10−7 (1,000 lg=L), 8:70× 10−10 (2,000 lg=L), and 1:17× 10−9 (4,000 lg=L).
Environmental Health Perspectives 107007-5 128(10) October 2020
and RQmed). Interestingly, even including the nondetects for cal-
culation of the MECmed, ciprofloxacin still posed an unacceptable
risk (RQmed; Figure S1).
Comparison of SELECT PNECRs to Previous PNECRs and
Ecotoxicological PNECs
Environmental PNECs (PNECENV; derived using standard eco-
toxicological tests on cyanobacteria) (Tell et al. 2019) and
PNECRs modeled using minimum inhibitory concentration data
from the EUCAST database [PNECRMIC (Bengtsson-Palme and
Larsson 2016)] were collated and compared with the SELECT
PNECRs determined in the present study (Table 2). PNECENVs
were overall more protective, although some PNECRMICs were
lower. Ciprofloxacin was the only antibiotic where the SELECT
PNECR (WWTP A influent, artificial sewage at 21°C) was most
protective and very similar to the PNECRMICs. Otherwise, qPCR
and SELECT PNECRs were the least protective for all antibiot-
ics, with the exception of trimethoprim, where the PNECENV
was the least protective.
Figure 2. Predicted no effect concentrations for resistance (PNECRs, logged) determined using the SELECT (blue triangle) and qPCR methods (pink circle).
Error bars represent the test concentrations directly above and directly below the NOECs used to calculate the PNECRs. For qPCR PNECRs, the most protec-
tive gene target is presented. This was ermF for the macrolides and intI1 for the remaining antibiotics. All data used to generate this figure are shown in
Table 1. qPCR PNECRs for azithromycin, clarithromycin, erythromycin, and ciprofloxacin were taken from Stanton et al. (2020). Note: PNECRs, predicted no
effect concentrations for resistance; qPCR, quantitative polymerase chain reaction; SELECT, SELection End points in Communities of bacTeria assay.
Table 1. All lowest observed effect concentrations (LOECs), no observed effect concentrations (NOECs) and corresponding predicted no effect concentrations





























AZ 750c 500c 50c 1,000 500 50 1,000 500 50 1,000 500 50
TAX 125d 62.5d 6.25d 31.25 15.63 1.56 15.63 7.81 0.78 15.63 7.82 0.78
CHL 500 250 25 250 125 12.5 ND ND ND ND ND ND
CIP 15.63c 7.81c 0.78c 1.95 0.98 0.1 15.63 7.82 0.78 0.976 0.49 0.05
CLA 750c 500c 50c 5,000 2,500 250 ND ND ND ND ND ND
ERY 750c 500c 50c 25,000 12,500 1,250 ND ND ND ND ND ND
GEN 250 125 12.5 250 125 12.5 ND ND ND ND ND ND
TRMP 62.5 31.25 3.13 31.25 15.63 1.56 125 62.5 6.25 250 125 6.25
Note: All data were generated in the present study unless otherwise indicated (c,d). The LOEC is the lowest concentration where a significant difference was observed compared with
the control. The NOEC is the test concentration directly below the LOEC. All PNECRs were determined by dividing the NOEC by an assessment factor of 10. Corresponding graphs
of average intI1 prevalence for cefotaxime, chloramphenicol, gentamicin, and trimethoprim are shown in Figure 1A–D, respectively. SELECT assays where the temperature was
reduced from 37 deg to 21 deg. SELECT T/AS refers to SELECT assays where the temperature was reduced from 37 deg to 21 deg AND artificial sewage (AS) was used instead of
Iso-Sensitest Broth. AZ, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CLA, clarithromycin; ERY, erythromycin; GEN, gentamicin; LOEC, lowest observed effect con-
centration; ND, not determined; NOEC, no observed effect concentration; PNECRs, predicted no effect concentrations for resistance; qPCR, quantitative polymerase chain reaction;
SELECT, SELection End points in Communities of bacTeria assay; TAX, cefotaxime; TRMP, trimethoprim.
aSELECT T LOECs, NOECs, and PNECRs refer to SELECT assays conducted in Iso-Sensitest™ broth at 21°C.
bSELECT T/AS LOECs, NOECs, and PNECRs refer to SELECT assays conducted in artificial sewage at 21°C.
cqPCR LOECs, NOECs, and PNECRs for AZ, CLA, ERY, and CIP were from Stanton et al. (2020). All macrolide values reported are based on ermF (compound-specific gene target);
CIP values reported are based on the intI1 target.
dqPCR LOECs, NOECs, and PNECRs for TAX using the blaCTX-M (compound-specific gene target) were from Murray et al. (2018). These are identical to the values based on the
intI1 target that were generated as part of the present study and are reported in Figure 1A.
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Discussion
The present study used a new growth-based assay (the SELECT
method) to determine PNECRs for a total of eight antibiotics,
spanning 6 of 9 single antibiotic classes [3rd subgroup, accord-
ing to the Anatomical Therapeutic Chemical classification (WHO
2019)]. In addition, qPCR PNECRs generated in the present study
and others (Murray et al. 2018; Stanton et al. 2020) with the
same experimental system were collated and compared with
SELECT PNECRs. There was very good agreement, indicating
the SELECT method to be a reliable, rapid, and cost-effective
method to rapidly generate selective end point data. This has
been repeatedly identified as a significant knowledge gap in envi-
ronmental and human health risk assessment (Ashbolt et al.
2013) given that currently it is unclear whether ecotoxicological
end points are protective of selection for AMR (Le Page et al.
2017). We showed that the SELECT method outlined in the pres-
ent study can be used to rapidly determine experimental PNECRs
for antibiotics that can a) inform release limits of antibiotics that
aim to reduce the evolution of AMR in situ; b) provide data that
can be used to study the evolution of different AMR mechanisms
in greater detail; and c) identify likely environmental hotspots of
AMR to which humans may be exposed.
Both the intI1 gene and compound-specific resistance genes
were used as qPCR end points to determine PNECRs for the mac-
rolides, ciprofloxacin and cefotaxime. For the remaining antibiot-
ics (chloramphenicol, gentamicin, and trimethoprim), only intI1
was used because the qPCR target because genes conferring
resistance to these antibiotics are frequently integron associated
(Partridge et al. 2009). A metagenomic approach could be used
to identify additional compound-specific targets for qPCR quanti-
fication (Murray et al. 2018); however, it has also been shown
that exposure of a sewage-derived microbial community to even
relatively high levels of ciprofloxacin and trimethoprim resulted
in more co-selection than selection for compound-specific resist-
ance genes (Murray et al. 2019). Macrolide-specific gene targets
generated lower PNECRs than intI1, which may be because
macrolide-resistance genes are not commonly integron associated
(Stanton et al. 2020); however, interestingly, cefotaxime PNECRs
using compound-specific (blaCTX-M) (Murray et al. 2018) and
intI1 gene targets (the present study) were identical. This sug-
gests that compound-specific gene targets to determine qPCR
PNECRs will not always be more protective than using intI1.
Class 1 integrons are considered a good indicator of environmen-
tal pollution owing to their ability to integrate different resistance
gene cassettes (Gillings et al. 2015), making them an appropriate
gene target to quantify the potential for selection as well as co-
selection. A single gene target such as intI1 that summarizes or
estimates total selection may also be an attractive regulatory end
point. This end point also has utility in human health risk assess-
ment, given that class 1 integrons are often clinically associated
with AMR (Ghaly et al. 2017).
For all antibiotics, with the exception of erythromycin and
clarithromycin, the SELECT PNECR was either identical or more
protective than the qPCR PNECR. This may be because, in the
Figure 3. Risk quotients ðRQsÞ=maximum measured environmental concentration (MECmax) or median measured environmental concentration
(MECmed)/lowest determined SELECT-predicted no effect concentration for resistance (PNECR). Here, MECmed values do not include the nondetects (for these
data, see Figure S1). MECs were extracted for all antibiotics except gentamicin from the Umweltbundesamt (UBA) Pharmaceuticals in the Environment data-
base. For gentamicin, predicted environmental concentration data were used. Risk was broadly classified in a traffic light color system. Red, bold
triangle= high risk (RQ>1), using MECmax; red, empty triangle= high risk (RQ>1), using MECmed; orange, bold square =medium risk (RQ>0:1 and <1),
using MECmax; green, bold circle = low risk (RQ<0:1), using MECmax; green, empty circle = low risk (RQ<0:1), using MECmed. Note: PNECR, predicted no
effect concentration for resistance; SELECT, SELection End points in Communities of bacTeria assay.
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previous study that determined the macrolide PNECRs reported
here, metagenome analyses showed that the predominant mem-
bers of the community were Gram-negative opportunistic patho-
gens belonging to Enterobacteriaceae, such as E. coli, Proteus
mirabilis, and Klebsiella pneumoniae (Stanton et al. 2020), and
macrolides are generally used to treat Gram-positive infections.
Therefore, it may be that there is minimal reduction in growth
because the majority of bacteria within the sample were already
(intrinsically) resistant.
With the exception of erythromycin, clarithromycin, and cipro-
floxacin, all qPCR PNECRs and SELECT PNECRs were within
one test concentration of each other. For comparison, when per-
forming the ASRIT, large variability is expected and results are of-
ten reported within orders of magnitude [e.g., 1 mg=L to 10 mg=L
(OECD 2009)], whereas most of the qPCR and SELECT values
did not differ by a factor >2. The SELECT method is also more
rapid and cost effective than the ASRIT test, which is currently rec-
ommended for environmental risk assessment of antibiotics (EMA
2018) despite evidence showing that it is insensitive to antibiotics
(Le Page et al. 2017).
The lower SELECT PNECR observed for ciprofloxacin was
likely due to the fact that resistance to ciprofloxacin is conferred
through multiple mechanisms, all of which are captured in the
SELECT method, as opposed to a single target with qPCR.
Presumably, one or more of these mechanisms has a lower fitness
cost than integron carriage. Previously, gyrA1 mutants have been
selected at concentrations of as low as 0:1 lg=L, which is the
lowest minimal selective concentration (MSC) determined to
date (Gullberg et al. 2011). In more elaborate biofilm experimen-
tal systems, the LOEC of ciprofloxacin was 1 lg=L, based on
higher qnrD relative abundance and significant effects on com-
munity structure (Kraupner et al. 2018). Selection for this mobile
resistance gene in the community occurred at a lower concentra-
tion than selection for gyrA mutations in E. coli isolated from the
same community (Kraupner et al. 2018). Therefore, mobile quin-
olone resistance genes may have a lower fitness cost compared
with chromosomal mutations in housekeeping genes. The lowest
SELECT PNECR for ciprofloxacin was 0:05 lg=L, which is
more comparable to these values than the previously determined
qPCR PNECR of 1:56 lg=L (Stanton et al. 2020). This lends fur-
ther support to reliability of the SELECT method and indicates
selective effect concentrations may be very similar, even across
different experimental systems (at least in the case of ciprofloxa-
cin, and possibly other fluoroquinolones).
This is further exemplified through our investigation of spa-
tiotemporal factors and culturing conditions. Spatiotemporal fac-
tors affecting the risk of selection were investigated by
comparing SELECT PNECRs determined using wastewater sam-
ples from different time points, geographical locations, or type of
sample (i.e., influent or effluent). PNECRs were very similar
overall, which suggests that a single PNECR for each antibiotic
could be applicable to many different environments. However,
the samples tested were all from the UK, serving rural or semi-
rural populations, and urban sewage serving much greater popu-
lations may yield different results. No significant differences in
PNECRs determined using influent or effluent indicates that influ-
ent samples may be sufficient for future testing. This would ena-
ble a PNECR to be determined in less than 15 h (including setup,
the experimental run, and data analyses), which is significantly
quicker than many current ecotoxicological tests, including those
currently recommended for assessment of antibiotics.
Potential limitations of the experimental conditions used for the
determination of qPCR and SELECT PNECRs are that the tempera-
ture (37°C) and nutrient content (Iso-Sensitest™ broth) are high
(compared with environmental conditions). To address this poten-
tial issue and to improve the environmental realism of the SELECT
assay, PNECRs for four antibiotics were determined with the
SELECT assay conducted at room temperature (21C±2C) and
with artificial sewage used as the growthmedium. Thismedium and
temperature range are used in the widely used Organisation for
Economic Co-operation and Development (OECD)-approved
ASRIT (OECD 2010). SELECT PNECRs were almost all identical
or very similar (i.e., within one test concentration), independent of
temperature or culture medium used. This suggests that the
SELECTmethod is also representative ofmore environmentally rel-
evant conditions (i.e., lower temperature and nutrient levels). The
largest discrepancywas observed for trimethoprim, where the artifi-
cial sewage, lower-temperature PNECR was four times that of the
Iso-Sensitest™, higher-temperature treatment. No single experi-
mental condition consistently gave the lowest PNECR for all four
tested antibiotics. This may be a reflection of changes in relative fit-
ness of bacteria harboring resistance or of preferential enrichment of
different species, which may be differentially favored under differ-
ent conditions.
The PNECRs determined in the present study were used to cal-
culate RQs for aquatic environments (hospital effluent, wastewater
influent and effluent) based on MEC data extracted from the UBA
database (UmweltBundesamt 2019) (except for gentamicin, which
used predicted environmental concentration data). Ciprofloxacin
posed the highest risk of selection for AMR, given that both the
RQmax and RQmed were >1 (derived using the low-temperature, ar-
tificial sewage SELECT PNECR), and, in the case of the RQmax,
this value approached 5,000. Trimethoprim, azithromycin, and
cefotaxime posed the next highest risks (RQmax > 1), indicating
selection is likely to occur in particularly impacted environments,
which has implications for human exposure and human health risk
assessment. For all antibiotics, with the exception of ciprofloxacin,
the RQmed was <0:1, which translates to a lower risk of selection.
Our data support the recommendation to include ciprofloxacin and
Table 2. Summary of environmental predicted no effect concentrations
(PNECENVs) derived using ecotoxicological tests, modeled predicted no effect
concentrations for resistance based on MIC data (PNECRMICs) and experimental
predicted no effect concentrations for resistance PNECRs determined in the
present study (qPCR and SELECT PNECRs) and previously published studies
[(some qPCR PNECRsc,d)] for all test antibiotics in the present study.
Antibiotic
PNECENV (lg=L)












Azithromycin 0.02 0.25 50c 50
Cefotaxime 0.1 0.13 6.25d 0.78
Chloramphenicol NA 8 25 12.5
Ciprofloxacin 0.57 0.06 0.78c 0.05
Clarithromycin 0.08 0.25 50c 250
Erythromycin 0.5 1 50c 1,250
Gentamicin 0.15 1 12.5 12.5
Trimethoprim 100 0.5 3.125 1.56
Note: Original data citations are in the column headers or denoted by footnotes (c,d), as
appropriate. LOEC, lowest observed effect concentration; NA, not available; NOEC, no
observed effect concentration; PNECENV, environmental predicted no effect concentra-
tion; PNECRMIC, predicted no effect concentration for resistance modeled using mini-
mum inhibitory concentration; PNECRs, predicted no effect concentrations for
resistance; qPCR, quantitative polymerase chain reaction; SELECT, SELection End
points in Communities of bacTeria assay; WWTP, wastewater treatment plant.
aLowest qPCR PNECRs reported for the gene target that gave the lowest, lowest
observed effect concentration. PNECRs were calculated by dividing the no observed
effect concentration by an assessment factor of 10.
bLowest SELECT PNECRs reported for the experimental conditions for any influent
sample (i.e., from WWTP A or B) that gave the lowest, lowest observed effect concen-
tration. PNECRs were calculated by dividing the no observed effect concentration by an
assessment factor of 10.
cData from Stanton et al. (2020).
dData from Murray et al. (2018). This is identical to the cefotaxime PNECR for the intI1
gene targeted, which was calculated as part of the present study.
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retain azithromycin on the second version of the European WFD
Watch List (Loos et al. 2018) but also suggest that trimethoprim
should be added on the basis of risk of selection for AMR. The
other two macrolides (clarithromycin and erythromycin) are also
included on the WFDWatch List, but only clarithromycin exerts a
medium risk of selection occurring in the most impacted environ-
ments (MECmax).
A comparison with previously published PNECs was also per-
formed. PNECENVs were most protective in most cases, except for
chloramphenicol, ciprofloxacin, and trimethoprim, where a PNECR
was more protective. In these three cases, SELECT PNECRs were
highly comparable to the PNECRMICs, indicating a good predictive
value of the PNECRMIC method. However, because our data are ex-
perimental as opposed to modeled, this also indicates that the
PNECRMIC method may be overestimating selective effects in some
cases. This comparison also strengthens the case for adding trime-
thoprim to the WFD Watch List on the basis of risk for selection,
given that the PNECENV was two orders of magnitude greater than
all PNECRs (PNECRMIC, qPCR PNEC
R, or SELECT PNECR), as
well as resulting in an RQmax > 1. This also highlights the need for
continued generation of data on selective end points, especially in
cases where the PNECENV is not determined (as with chlorampheni-
col). This is particularly pertinent because AMR is a potential
human health hazard not currently considered by standard ecotoxi-
cological approaches. The SELECTmethod will be useful for rapid
data generation for antibiotics such as chloramphenicol, where eco-
toxicological PNECdata do not exist.
Our data also support a recent meta-analysis that compared dif-
ferent ecotoxicological PNECs and PNECRs (Le Page et al. 2017).
PNECs in cyanobacteria were themost protective of the ecotoxico-
logical end points included; however, they were not always more
protective than PNECRs. The reasons for this are unclear but may
indicate higher sensitivity to some antibiotics in some cyanobacte-
rial species, as suggested previously (Le Page et al. 2017), com-
pared with the sewage communities used in the SELECT method.
Therefore, as in the previous study, we recommend cyanobacterial
PNECs be used in conjunctionwith experimental PNECRs (such as
those generated using the SELECT method) to ensure maximum
protection of both the environment and human health.
The current environmental risk assessment is based on single
compounds, and an issue so far unaddressed is the fact that bacte-
rial communities in sewage, or in the environment, are exposed
to a complex mixture of antibiotics and other co-selective com-
pounds such as biocides or heavy metals. Therefore, additive or
synergistic effects of compounds with selective effects are likely
to result in lower PNECRs and higher RQs. Additional research
into the effects of mixtures of selective compounds is required to
understand the true risk of selection/co-selection for AMR occur-
ring in aquatic environments. In addition, emerging data on
MECs in low- and middle-income countries (J. Wilkinson and
A. Boxall, personal communication) will result in significantly
higher MECmax, MECmed, and RQ values. Therefore, the global
risk of selection will be greater than reported here.
In conclusion, the present study reports the largest set of empir-
ical selective endpoint data determined within the same experi-
mental system. For all antibiotics tested except clarithromycin and
erythromycin, the novel SELECT method generated more protec-
tive end points than those derived using qPCR in previously pub-
lished experimental studies (Murray et al. 2018; Stanton et al.
2020). The SELECT method is recommended for rapid generation
of further selective endpoint data for antibiotics and other antimi-
crobials, including the effects of complex mixtures. These data can
be used to inform environmental and human health risk assessment
of AMR. The data presented support the inclusion of azithromycin
and ciprofloxacin as priority substances and suggest that
trimethoprim and possibly cefotaxime should also be considered
for the next WFD Watch List on the basis of risk of selection for
AMR. By reducing selection for AMR in the natural environment,
the risk of human exposure to AMR is also likely to be reduced.
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